Your session is about to expire
← Back to Search
Microbiome Formulation
Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia
Phase 1
Waitlist Available
Led By Thomas Wolever, MD/PhD
Research Sponsored by NuBiyota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline vs. week 7
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this pilot study is to determine the effects of two human microbiome formulations (MET-3 and MET-5) on fasting serum TG concentration.
Eligible Conditions
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline vs. week 7
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline vs. week 7
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Fasting blood lipid levels
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: MET-5 2.5 g daily for 4 weeksExperimental Treatment1 Intervention
MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
Group II: MET-3 2.5 g daily for 4 weeksExperimental Treatment1 Intervention
MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
Find a Location
Who is running the clinical trial?
NuBiyotaLead Sponsor
8 Previous Clinical Trials
221 Total Patients Enrolled
1 Trials studying Obesity
15 Patients Enrolled for Obesity
Thomas Wolever, MD/PhDPrincipal InvestigatorINQUIS Clinical Research